Related Experiment Videos
The calpastatin defect in hypertension is possibly due to a specific degradation by calpain
F Salamino1, B Sparatore, R De Tullio
1Institute of Biological Chemistry, University of Genoa, Italy.
Insights
Essential hypertension reduces calpastatin activity in red blood cells, but therapy restores it. Increased calpain protease activity may explain lower calpastatin levels in hypertension.
Area of Science:
- Biochemistry
- Physiology
- Hypertension Research
Background:
- Essential hypertension is linked to reduced calpastatin activity in erythrocytes.
- Calpastatin is a key inhibitor of the calpain protease system.
Purpose of the Study:
- To investigate the role of calpain-mediated degradation in reduced calpastatin activity in essential hypertension.
- To compare calpastatin degradation rates in human and rat erythrocytes.
Main Methods:
- Assessed calpastatin activity in erythrocytes from hypertensive patients and rats.
- Investigated the degradation of calpastatin by homologous calpain in red blood cells.
Main Results:
- Calpastatin activity was significantly reduced in hypertensive patients' erythrocytes.
- Therapeutic treatment normalized calpastatin activity in parallel with blood pressure reduction.
- Calpastatin degradation by calpain was observed in both human and rat erythrocytes, with a ~5-fold higher rate in rats.
- Increased proteolytic degradation by calpain may explain lower calpastatin levels in hypertension.
Conclusions:
- Therapeutic interventions can restore red blood cell calpastatin activity in essential hypertension.
- Calpain-mediated degradation of calpastatin is a significant factor in its reduced levels during hypertension.
- Differences in calpain activity may explain variations in calpastatin levels between human and rat hypertension models.
Abstract:
Calpastatin activity, significantly reduced in erythrocytes of patients affected by essential hypertension, is restored to normal values by appropriate therapeutical treatments in a time-dependent fashion and in parallel with the decline in blood pressure. Evidence is also presented indicating that red cell calpastatin is degraded in human and rat red cells by homologous calpain, and that the rate of degradation is approx. 5-times higher in rat erythrocytes. Thus, increased proteolytic degradation catalyzed by calpain could explain both the decrease in the amount of calpastatin activity and the profound difference between the intracellular level of the calpain inhibitor observed in erythrocytes from patients with essential hypertension and the genetically hypertensive rats.